NVO’s Ozempic Outshines LLY’s Mounjaro in Lowering Cardiovascular Risk
Novo NVO announced new real-world data from the COMPETE SWITCH Cardiovascular (CV) study comparing treatment strategies in adults…
Novo’s CagriSema Outshines Zepbound in Key Phase III Weight-Loss Study
Novo NVO announced top-line results from two phase III studies evaluating once-weekly CagriSema, its investigational fixed-dose combination of…
LLY’s Oral GLP-1 Pill Scores Another Pair of Diabetes Wins
Eli Lilly LLY announced positive top-line data from two late-stage studies evaluating orforglipron, its once-daily oral GLP-1 pill, in…